Results 161 to 170 of about 41,944 (264)

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

New England Journal of Medicine, 2017
M. Robson, S. Im, E. Senkus, Bing-he Xu, S. Domchek, N. Masuda, S. Delaloge, Wei Li, N. Tung, A. Armstrong, Wenting Wu, C. Goessl, S. Runswick, P. Conte   +13 more
semanticscholar   +2 more sources

Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas

Cell Death and Disease
Occurrence of resistance to olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) approved in ovarian carcinoma, has already been shown in clinical settings.
M. Chiappa, A. Decio, L. Guarrera, Ilaria Mengoli, Anju Karki, Divora Yemane, C. Ghilardi, Eugenio Scanziani, Simone Canesi, M. C. Barbera, I. Craparotta, Marco Bolis, R. Fruscio, Chiara Grasselli, T. Ceruti, Massimo Zucchetti, Jesse C. Patterson, Robin A. Lu, Micheal B. Yaffe, M. Ridinger, G. Damia, F. Guffanti   +21 more
semanticscholar   +1 more source

Isocitrate Dehydrogenase Mutations in Cancer: From Bench to Bedside Applications

MedComm, Volume 7, Issue 5, May 2026.
Mutant isocitrate dehydrogenase affects multiple cancer types. Alterations in IDH1 and IDH2 result in abnormal enzyme activity, leading to the overproduction of D‐2‐hydroxyglutarate (D‐2HG). This metabolite disrupts cellular metabolism and epigenetic regulation, driving cancer initiation, progression, and metastasis.
Yuhan Fang, Xiaoqing Wang, Kai Luo, Tikam Chand Dakal, He Bai, Caiming Xu, Guixin Zhang   +6 more
wiley   +1 more source

Olaparib enhancing radiosensitization and anti-metastatic effect of oral cancer by targeting IL-17A signal

Cancer Cell International
Purpose We tested whether the PARP inhibitor, Olaparib, can effectively enhance radiosensitivity while inhibiting OSCC growth and metastasis in vitro and in vivo. Patient samples were used for survival validation.
Chih-Chia Yu, Hon-Yi Lin, Michael W.Y. Chan, Shu-Fen Wu, Wen-Yen Chiou, Moon-Sing Lee, Chen-Lin Chi, Ru-Inn Lin, Feng-Chun Hsu, Hsuan-Ju Yang, Liang-Cheng Chen, Chia-Hui Chew, Shih-Kai Hung   +12 more
doaj   +1 more source

Validation of a UPLC-MS/MS Method for Quantifying Intracellular Olaparib Levels in Resistant Ovarian Cancer Cells

Pharmaceuticals
Background: Ovarian cancer remains one of the leading causes of cancer-related mortality among women and constitutes a major unmet medical need. A common treatment-limiting factor for ovarian cancer patients is resistance to Poly(ADP-ribose) polymerase ...
Szymon W. Kmiecik, Jennifer Lewis, Jonas Schwickert, Henrik Breitenreicher, Martin R. Sprick, Jürgen Burhenne   +5 more
doaj   +1 more source

RNA Modifications: Current Understandings and Future Perspectives

MedComm, Volume 7, Issue 5, May 2026.
Types of RNA modification. We have summarized the currently common types of RNA modifications, including ac4C, m6A, m1A, m5C, m3C, m7G, and ψ, and visually characterized their features through structural formulas. The characteristic structures are marked with a background color different from the background color.
Shiyu Xiao, Tingwen Xiang, Chuan Yang, Xiaohua Wang, Gang Huang, Fei Luo, Zhao Xie, Yueqi Chen   +7 more
wiley   +1 more source

Targeting Tumor Stroma: Current Challenges and Future Directions

MedComm, Volume 7, Issue 5, May 2026.
Figure 1. Mechanism of ECM reprogramming. Cancer‐associated fibroblasts (CAFs), cancer‐associated macrophages (CAMs), and other mesenchymal cells alter the ECM composition and increase its stiffness by depositing matrix components such as collagen and hyaluronic acid, and secreting cross‐linking agents like lysyl oxidase homolog 2 (LOXL2).
Siwei Wang, Haofan Hu, Weifeng Zeng, Lu Qin, Xiaoping Chen, Zhibin Liao, Furong Liu, Zhanguo Zhang   +7 more
wiley   +1 more source

Pulmonary Embolism Associated with Olaparib in BRCA2-Mutated Prostate Cancer: A Case Report

Current Oncology
Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor approved for treating metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations, has significant clinical benefits.
Shuhei Ishii, Shigekatsu Maekawa, Fumiko Amano, Daichi Kikuchi, Daiki Ikarashi, Renpei Kato, Mitsugu Kanehira, Ryo Takata, Jun Sugimura, Wataru Obara   +9 more
doaj   +1 more source

The Contribution to the Assignment of Defined Daily Dose (DDD) to Antineoplastic Drugs of the Italian Working Group on DDD

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 5, May 2026.
ABSTRACT Purpose To report the experience of the Italian Working Group on DDD (Ita‐DDD‐wg) in assigning DDDs to a list of antineoplastic agents. Methods Active substances from the ATC L01 group with no assigned DDD and reimbursed at least once during 2021 by the Italian Healthcare Service were identified.
Angela Boccia, Giulia Hyeraci, Anna Girardi, Rosa Gini, Gianluca Trifirò, Ylenia Ingrasciotta, Andrea Spini, Valentina Ientile, Elisabetta Poluzzi, Giampiero Mazzaglia, Ippazio Cosimo Antonazzo, Casula Manuela, Elena Tragni, Olivia Leoni, Arianna Mazzone, Michele Ercolanoni, Martina Zanforlini, Ursula Kirchmayer, Belleudi Valeria, Marco Finocchietti, Francesco Barone‐Adesi, Giuseppe Roberto   +21 more
wiley   +1 more source

Clinical Impact of Olaparib for Platinum-Sensitive Recurrent Ovarian Cancer

Diseases
Background/Objectives: Olaparib, a poly ADP ribose polymerase inhibitor, has been effective in prolonging progression-free survival in platinum-sensitive recurrent ovarian cancer.
Hiroaki Ishida, Megumi Manrai, Akiko Takashima, Hiroki Egashira, Mizuki Nonaka, Hideaki Shimada   +5 more
doaj   +1 more source